Truitt Joseph

SEC Form 4 insider trading activity

Truitt Joseph has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.

On the most recent filing, Truitt Joseph is listed as Director at Larimar Therapeutics, Inc. Inside the rolling window, Truitt Joseph reported 1 open-market purchase totaling $10K in LRMR and no open-market sales.

Companies traded

Other insiders at LRMR

Insider Buying

$10K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
LRMRPurchase$10KNov 12SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Truitt Joseph made?

Truitt Joseph has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.

Which companies does Truitt Joseph trade?

Truitt Joseph has filed SEC Form 4 disclosures for 1 company, including LRMR.

When was Truitt Joseph's most recent SEC Form 4 filing?

Truitt Joseph's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.

What is Truitt Joseph's total buy and sell value in the current window?

Inside the rolling retention window, Truitt Joseph bought $10K and sold $0 based on SEC Form 4 filings.

What was Truitt Joseph's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 3,500 LRMR shares on 2026-11-11, worth $10K, per SEC Form 4 filings.